Navigation Links
Neurobiological Technologies' Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
Date:6/1/2009

long-term tolerability of XERECEPT(R). Of the 113 patients enrolled, a total of 32 patients have completed one year or more of treatment in the study. Dexamethasone dosing of all patients on study was reduced progressively over time. Patients from the placebo cohort in the blinded studies entered this study with approximately double the mean dexamethasone dosing of patients from the prior active treatment cohort. The patient dosing of dexamethasone was reduced sharply once on XERECEPT(R), such that the difference between the two was no longer significant at 4 weeks. More than 50 percent of patients completing six months on study were able to achieve a virtual or complete elimination of corticosteroid treatment, and to sustain this for extended periods of time. The NTI-0501 study also showed that XERECEPT(R) therapy was well tolerated over extended periods up to two years or more.

"We are delighted to see the results from the three Phase III studies, the analysis of the brain scans from these studies, and the intriguing preclinical data regarding XERECEPT(R)," said Stephen Evans-Freke, co-Managing General Partner of Celtic Pharma. "We are especially interested in the data from the blinded and open-label studies indicating that XERECEPT(R) may offer significant clinical benefit for metastatic patients, given the very poor options available now for this substantial patient population. We look forward to reviewing these results with FDA and their European and Japanese counterparts before determining the forward path for this promising drug."

NTI-0302

NTI-0302, a Phase III randomized, double-blind study comparing XERECEPT(R) to dexamethasone for the control of acute symptoms associated with peritumoral edema, was discontinued due to slow enrollment. The study results from the 37 patients who enrolled show that XERECEPT(R) was as effective as 4mg/day of dexamethasone in the treatment of patients presenting with an a
'/>"/>

SOURCE Neurobiological Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
2. Neurobiological Technologies Announces Viprinex(TM) Does Not Pass Interim Futility Analysis
3. Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data
4. Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke Trials
5. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
6. Fifth DSMB Meeting Supports Neurobiological Technologies Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod)
7. Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimers Disease
8. TriLink BioTechnologies, Inc. Announces Supply Agreement With Osmetech Molecular Diagnostics
9. B. Braun Medical Inc. to Demonstrate Infusion Systems Technologies at HIMSS 2009 Interoperability Showcase
10. MultiCell Technologies Signs Liver Stem Cell R&D Agreement To Develop Products for the Study of Liver Cancer
11. U.S. Food and Drug Administration Clears Way for Multi-Center Clinical Trial of IDEV Technologies SUPERA Peripheral Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Calif. , Oct. 21, 2014 Influenza will ... flu-associated deaths in the United States ... viruses are thought to spread is from person to person ... Ebola has a serve way of death, but kills much ... Ebola is also done by human fluids including sweat, saliva, ...
(Date:10/22/2014)... , Oct. 22, 2014 Sanomedics International ... 2014 report by Global Research & Data Services, demand ... year from 2014 through 2018, as demand for more ... is the world,s largest market for thermometers, ... advanced thermometers is Sanomedics International Holdings, Inc. ...
(Date:10/22/2014)... 2014 Provectus Biopharmaceuticals, Inc. (NYSEMKT: PVCT) specializes ... investigational drug for cancer, is designed for injection into ... Its oncology focus is on melanoma, breast cancer and ... trials of PV-10 as a therapy for metastatic melanoma, ... dermatitis and psoriasis. This summer, the ...
Breaking Medicine Technology:WholeHealth Products is proud to be releasing its Influenza A and B combo test, on the heels of the announcing of its phase 2 completion of the Rapid Ebola Test 2Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2
... ultra rapid acting insulin presented at the American Diabetes ... ORLEANS, June 6 /PRNewswire-FirstCall/ -- ... investigational ultra rapid acting insulin AFRESA(R) (insulin human [rDNA ... to standard of care therapies in controlling post-meal blood ...
... June 6 Boehringer Ingelheim Pharmaceuticals, Inc. today announced ... the type 2 diabetes therapeutic area. The Company ... clinical development worldwide. New Phase II data results ... inhibitor and the Company,s lead diabetes compound, were presented ...
Cached Medicine Technology:Studies Show AFRESA(R) Controls Post-Meal Sugar Levels With Less Weight Gain and Hypoglycemia Risk for Diabetes Patients 2Studies Show AFRESA(R) Controls Post-Meal Sugar Levels With Less Weight Gain and Hypoglycemia Risk for Diabetes Patients 3Studies Show AFRESA(R) Controls Post-Meal Sugar Levels With Less Weight Gain and Hypoglycemia Risk for Diabetes Patients 4Boehringer Ingelheim Unveils Diabetes Pipeline 2Boehringer Ingelheim Unveils Diabetes Pipeline 3Boehringer Ingelheim Unveils Diabetes Pipeline 4Boehringer Ingelheim Unveils Diabetes Pipeline 5
(Date:10/22/2014)... TX (PRWEB) October 22, 2014 On ... Criminal Minds featuring skin diseases both fictional and ... (CEHMDF), a nonprofit organization committed to advocacy and ... if CBS will take the opportunity to impart truth ... , There are many misconceptions about ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Isabel ... of Allied Health Professions (ASAHP) Conference on October 22-24 ... CEO will participate in a panel discussion on Technology ... , Isabel Healthcare provides a diagnostic decision support tool ... the diagnosis skills of students and clinical learners. The ...
(Date:10/22/2014)... Amy Norton HealthDay Reporter , ... on the three Ebola cases in Dallas. But, mental health ... to Americans. President Barack Obama on Friday appointed an ... which has infected two Dallas nurses who cared for a ... Health Presbyterian Hospital. But the U.S. cases are miniscule ...
(Date:10/22/2014)... October 22, 2014 Shriners Hospitals for ... will change the current location of Shriners Hospitals for ... Limestone across from the University of Kentucky Albert B. ... ambulatory care center, owned and operated by Shriners Hospitals ... needs of children and their families well into the ...
(Date:10/22/2014)... October 22, 2014 Hay House is pleased ... Addiction and Upgrade Your Life (Paperback; $10.82) written by the ... & Recovery. This book is meant to help readers ... life of recovery. , Recovery 2.0 is not the ... Recovery 2.0 is a guide for what comes next. ...
Breaking Medicine News(10 mins):Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 2Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 3Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3
... rare liver transplant surgery has been conducted by Indian doctors ... boy. The surgery took place at the Asha Dinesh Institute ... child who was afflicted by a congenital disease. ... who was born with itching and jaundice was now near ...
... drug addicts is beginning to yield results in Scotland, with ... 2004. Heroin users accounted for 8,000 of this figure. //This ... trying to get back to normal life. ... said that the percentage of heroin users is falling. About ...
... Proteins are stable there are certain conditions under ... the unbounded proteins leading to protein aggregation called ... responsible for causing neurodegenerative disorders such as Alzheimer ... Autònoma de Barcelona, led by the researcher Salvador ...
... stem cells, which can be effectively fused with other cells ... to a study.// ,Researchers at Oregon Health and Science ... in fighting disease. , ,The researchers, headed by Markus ... 1, which causes jaundice and cirrhosis of the liver, can ...
... on Wednesday doctors and hospitals in the global healthcare destination ... ,Six hospitals in Chennai, two in Kumbakonam, 350 km from ... were raided by 300 IT officials simultaneously. About Rs.6 million ... worth several millions were seized in the raids from the ...
... found to be responsible for transferring the amino ... for reducing oxidative stress as Cysteine present in ... activity in brain.// Free radicals are responsible for ... Raymond Swanson and his team from Neurology and ...
Cached Medicine News:
... flexible Mediprene® material, Available in even sizes ... nasal airway maximizing patient comfort. The Latex-Free ... patient comfort while offering the best solution ... allowing you to offer a quality latex-free ...
Soft PVC. Available in sizes 12-36F, Interior striations for smooth suction catheter insertion. Bevel tip. Single use. Sterile....
Color Coded Guedel Oral Airways are individually bagged, latex free, and color Coded for size identification....
Flexible vinyl with a rigid bite block. Guedel-style with three internal channels. Individually packaged, 48 per case. Latex Free....
Medicine Products: